{"description":"Angiex develops TM4SF1-directed antibody-drug conjugate therapies for the treatment of solid cancers. They exploit a unique biology, which is essential to both angiogenesis (which enables tumors to grow) and invasion and metastasis (which accounts for most cancer mortality).","height":1080,"html":"<div style=\"position:relative;padding-bottom:56.25%\"><iframe src=\"https://skiv.com/embed/bxvgNGd\" style=\"width:100%;height:100%;position:absolute;left:0;top:0\" frameborder=\"0\" allow=\"fullscreen\" allowfullscreen></iframe></div>","provider_name":"Skiv","provider_url":"https://skiv.com","thumbnail_height":198,"thumbnail_url":"https://cdn.skiv.com/u/LPDfybK/3a695f846206082ea6e1b9aa5b34c7135f68f6591b4723db543768a1527b4a83/thumbnails/thumbnail.jpg","thumbnail_width":352,"title":"May 2025 Northwest Forums: AngieX","type":"video","url":"https://skiv.com/v/bxvgNGd","version":"1.0","width":1920}